Skip to content

IDEXX Laboratories Inc

US · IDXX #543 by market cap Listed 1970
676.21 -13.44 -1.95%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

✦ Quant Fair Value how this is computed

Near fair value
549.23 fair value ≈ 652.95 756.68
  • Implied fair-value range of 549.23-756.68, from this stock's own trailing 5-year average P/E applied to trailing EPS.
  • Current price is +3.6% above the average-multiple fair value of 652.95.

Valuation each multiple against its own 5-year range

P/B ratio 28.50 Cheap vs history 33rd percentile
5-year average 39.97 · #39 of 41 in Diagnostics & Research
P/E ratio 45.57 In line with history 34th percentile
5-year average 49.92 · forward 41.58 · #16 of 20 in Diagnostics & Research
P/S ratio 11.43 In line with history 59th percentile
5-year average 11.13 · forward 10.51 · #36 of 44 in Diagnostics & Research

Vs. peers Diagnostics & Research

Company Market cap P/E (TTM) P/B Div yield
IDEXX Laboratories Inc (IDXX) 53.28B 45.57 28.50 0.00%
Thermo Fisher Scientific (TMO) 248.08B 35.31 4.53 0.27%
Danaher (DHR) 155.03B 36.12 2.89 0.69%
Agilent Technologies (A) 48.04B 33.61 6.52 0.59%
Waters (WAT) 43.29B 184.29 2.83 0.00%
IQVIA Holdings (IQV) 40.51B 29.91 6.08 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★☆☆☆☆ Fair value470.00 Economic moatWide UncertaintyMedium Capital allocationExemplary

Trading 30.5% above Morningstar's fair value estimate.

Analyst note

Idexx's third-quarter results showed top-line and bottom-line year-over-year growth of 10% and 16%, respectively, supported by VetLab consumables and reference lab revenue that increased in double digits. Shares are up 20% at the time of writing.

Why it matters: Idexx's prowess in innovation has outweighed weakness in vet visits stretching back to 2024. We think the firm's ability to deliver meaningful technological advances has allowed practice revenue to grow reliably even as visits have eroded. Placement of the new InVue Dx platform has been impressive in its first year of release, and we expect the installed base to exceed 13,000 by the end of the year, up from 11,000 today. InVue's automated fluidics system eliminates the labor-intensive process of preparing traditional slides for cytology, which also reduces the chances of processing error. This makes testing for canine ear infections faster, more efficient, and more accurate.

The bottom line: While we've adjusted our full-year assumptions to reflect slightly stronger revenue growth and improved gross margin, this wasn't enough to shift our $470 fair value estimate. Shares remain overvalued, reflecting unrealistic growth expectations. We continue to project 9% annual revenue growth and 12% earnings growth, on average, through our explicit forecast period, supported by wide-moat Idexx's stream of new assays for its multiple testing platforms. We're watching the adoption of Idexx's new Cancer Dx panels, especially with the recent addition of the test for canine mast cell tumor—one of the most common cancers in dogs. This allows for early detection in high-risk dogs.

Long View: Recent industry data suggest significant declines in puppy adoption and puppy vet visits, offset by aging dogs that need more medical care. However, once the older dogs are gone, the puppy bust could translate into a smaller dog population, leading to volume decline.

Fair value

We're holding steady on our fair value estimate of $470 per share, which reflects the robust launch of the Invue analyzer as well as solid mid-single-digit growth in the reference labs.

We expect Idexx to benefit from higher long-term demand for pet diagnostics, as the pandemic-driven surge in pet adoption has led to increased pet ownership penetration, particularly among puppies and kittens adopted since 2020. We estimate average annual revenue growth of 8% through 2030. We remain most bullish about VetLab consumables and the reference lab segments—the two largest product lines in the companion animal segment. Despite the slowdown in instrument placement during the pandemic, Idexx has resumed its aggressive placement of analyzer units, helped by the new Invue platform, which should lead to VetLab consumable revenue growth that averages in the low double digits through 2030. Considering the opportunities for cross-selling and Idexx's ongoing progress in penetrating new animal hospitals with its analyzer instruments, we believe there is plenty of potential for the sales consultants to sell new services and develop stickier relationships.

Economic moat

We think Idexx has dug a wide economic moat that rests on the firm’s intangible assets that have complemented switching costs in supporting highly attractive economic profits over the last two decades.

Idexx is the leader in point-of-care diagnostic tests and in-house analyzer equipment, and holds a well-established position in the reference lab duopoly with VCA (now part of privately held Mars). Idexx's economic moat is driven by several sources.

First, Idexx benefits from a layer of switching costs across a number of its products. For example, with Idexx's practice and information management software, once the animal hospital staff has invested the time to enter all the patient and client information and become familiar with the software, the inconvenience of installing and learning a whole new system means customers tend to stick with Idexx. The same principle applies to its in-house test equipment. Once the practice has installed the base equipment and trained its vet techs on it, practices are more likely to stick with Idexx than to switch to another brand, which leads to a continuing stream of high-margin revenue from proprietary assays.

Customer switching costs also rise further if the vet practice purchases multiple Idexx products and services. For example, the integration of Idexx reference lab data and Idexx in-house analyzer data with Idexx practice management software makes the workflow smoother, and simplifies the transmission of test data and patient medical records. This leaves customers more reluctant to switch to another vendor. These switching costs have driven retention rates for analyzer consumables, the reference lab, and the highest-volume rapid assay test to 99.5%, 97.6%, and 97%, respectively.

Second, the firm also relies on intangible assets, including technical know-how and some intellectual property in its diagnostic tests. Idexx's key competitive advantage is its ability to consistently innovate in diagnostic tests. The firm has come up with new generations of assays and laboratory equipment that can test for more diseases and apply emerging diagnostic technology previously invented for humans to production animals and water testing, as well as companion animals. Idexx's products and services typically focus on testing for new types of diseases and parasites, improving turnaround time on test results, increasing the accuracy of results, and enhancing the convenience of on-site testing. As a result, Idexx and its rivals compete on the basis of product features rather than price. The latest in Idexx's lineup of diagnostics is the Invue analyzer that handles blood morphology and cytology tests.

Beyond these technology-based intangibles, Idexx’s major secret weapon lies in its sales representatives and field organization that provide high-touch service to animal hospitals. Idexx reps have proven themselves successful in providing counsel on optimizing hospital operations and improving the profit profile for vets. We have yet to see any other animal health firms carve out this sort of integrated role in animal hospital operations. We think Idexx’s commercial organization, level of service, and its strong relationships with vets is why Idexx was able to switch to direct distribution of its rapid test kits and analyzer consumables in 2015—despite holding a near-monopoly position with the three largest animal health distributors—without a hint of competitive pressure.

Finally, we think Idexx’s reference lab also enjoys elements of cost advantage over most other diagnostic labs because of its extensive scale. Though this aspect of Idexx is limited to its reference lab and doesn’t seem substantial enough for us to consider this as another source of moat for the entire enterprise, it bears noting, from our perspective. With a large, national lab network, Idexx is able to run these tests at lower costs thanks to higher throughput. Volume, route density, and ensuing efficient use of the labs result in more attractive margins than smaller-scale independent labs can offer.

Bull case

Unlike human healthcare, pet health services and products require cash payments—thereby bypassing the reimbursement issues and pricing pressure associated with third-party payers.

Anecdotal information from vets suggests that Idexx's well-integrated and user-friendly practice management software helps hospitals switch to and stick with Idexx's products and services.

Idexx's sales and customer support staff garner high marks for providing high-touch service to vet practices.

Bear case

International sales account for a substantial chunk of Idexx's total revenue; as the US dollar strengthens, Idexx would feel the pain on its top and bottom lines.

Idexx's rapid assay product line is most vulnerable to competitive pressure through the vet distributors. The firm could see growth in this area stagnate or decline.

Shares typically trade at a high multiple to forward earnings, so even a small pullback in pet healthcare spending could result in a material drop in share price.

By Debbie S. Wang

Quote time 2026-11-20 20:02:16 · For reference only, not investment advice and not tailored to your situation.

IDEXX Laboratories Inc discussion 0 comments

Add a comment